United Therapeutics (UTHR) Cash & Current Investments (2009 - 2026)

United Therapeutics has reported Cash & Current Investments for 18 years, with the latest figure at $2.2 billion in Q1 2026.

• Quarterly Cash & Current Investments fell 35.15% year-over-year to $2.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.2 billion (down 35.15% YoY) and the FY2025 annual result came in at $2.9 billion, down 10.61% from the prior year.
• Cash & Current Investments slipped to $2.2 billion in Q1 2026 per UTHR's latest filing, from $2.9 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $3.3 billion in Q3 2024 and troughed at $2.2 billion in Q1 2026.
• A 5-year average of $2.8 billion and a median of $2.9 billion in 2023 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2026: Cash & Current Investments surged 47.03% in 2022, then sank 35.15% in 2026.
• Over 5 years, Cash & Current Investments stood at $2.8 billion in 2022, then gained by 5.47% to $3.0 billion in 2023, then increased by 9.11% to $3.3 billion in 2024, then slipped by 10.61% to $2.9 billion in 2025, then fell by 26.25% to $2.2 billion in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $2.2 billion, $2.9 billion, and $2.8 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.